Skip to main
NTLA
NTLA logo

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

Intellia Therapeutics (NTLA) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 28%
Buy 39%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Intellia Therapeutics is positioned for a positive outlook due to its innovative use of Crispr/Cas9 technology to address high unmet medical needs in genetically defined diseases, which enhances its market potential. The company's financial model anticipates a significant reduction in operating expenses, projected to decrease from $600 million annually to $150 million by 2034, contributing to improved profitability. Additionally, revisions to the expected penetration rates for its therapies NTLA-2001 and NTLA-2002 have been increased to 10% from a previous 3.5%, signaling confidence in the therapeutics' market adoption amid a competitive landscape.

Bears say

Intellia Therapeutics exhibits a significantly negative outlook due to a 95% decline from its all-time highs, suggesting a waning investor confidence in the gene editing sector as a whole. The company faces substantial clinical and regulatory risks, including potential delays in trial initiation and the possibility that therapies may not gain approval from global regulatory agencies, which could further impair financial performance. Additionally, there exists a heightened "headline risk" whereby negative news surrounding gene editing technology, even if unrelated to Intellia’s specific efforts, could adversely affect the company's stock value.

Intellia Therapeutics (NTLA) has been analyzed by 18 analysts, with a consensus rating of Buy. 28% of analysts recommend a Strong Buy, 39% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Intellia Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Intellia Therapeutics (NTLA) Forecast

Analysts have given Intellia Therapeutics (NTLA) a Buy based on their latest research and market trends.

According to 18 analysts, Intellia Therapeutics (NTLA) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Intellia Therapeutics (NTLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.